Corcept Therapeutics

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Corcept Therapeutics reports robust earnings, navigates legal challenges for growth

Corcept Therapeutics demonstrated strong financial performance, stability, and strategic investments in key areas of its business.
While facing legal challenges and adapting to industry changes, the company capitalized on opportunities for growth and innovation.
Overall, Corcept's focus on clinical advancements and strategic investments positions it well for future success and expansion in the healthcare sector.

Corcept Therapeutics reports revenue growth, legal battles with Teva

Corcept Therapeutics delivered strong Q1 performance with revenue growth and a robust financial position.
The company faces challenges in managing expenses, legal battles, and sustaining R&D investments.
Opportunities lie in sales force expansion, clinical trials, and upcoming studies for growth and innovation.
Overall, Corcept's strategic focus on growth and legal defense positions it for future success in the market.

Corcept Therapeutics reports robust Q2 earnings and expands treatment reach

Corcept Therapeutics delivered strong financial performance, raised revenue guidance, and showcased progress in clinical development programs.
While facing legal challenges and market expansion complexities, the company's proactive strategies and positive trial results position it well for future growth.
Opportunities in partnerships, physician engagement, and broadening disease applications underscore Corcept's potential for continued success and impact in the healthcare industry.

Corcept Therapeutics excels in Q3, eyes growth in new markets

Corcept Therapeutics demonstrated robust financials, strategic wins in legal battles, and a focus on market expansion and product innovation.
While facing challenges in maintaining competitive positioning and navigating regulatory landscapes, the company is poised for growth.
With a strong performance in Q3 2023 and promising opportunities ahead, Corcept is well-positioned to capitalize on its strengths and drive future success.

Corcept Therapeutics reports robust Q4 revenue and diversifies pipeline

Corcept Therapeutics demonstrated strong financial performance in Q4 2023 with revenue growth and profitability.
The company's ongoing research and diversified pipeline position it well for future growth.
Challenges include legal disputes and market competition, but strategic planning and label expansions offer opportunities.
Overall, Corcept's financial stability, confidence in growth, and focus on treatment efficacy are key takeaways.

Corcept Therapeutics reports robust Q1 performance and eyes market expansion

Corcept Therapeutics delivered strong financial performance in Q1 2024, with revenue growth, increased net income, and raised revenue guidance.
The company's focus on innovative treatments for hypercortisolism and various cancers positions it well for future growth and market expansion.
While facing challenges like legal battles and operational complexity, Corcept remains optimistic about its pipeline and market potential.

Corcept Therapeutics reports strong Q2 performance amidst pipeline advancements

Corcept Therapeutics demonstrated robust financial performance and commercial growth in Q2 2024, supported by a strong cash position.
The company's pipeline strength was evident through positive study results for relacorilant and ongoing trials in various medical conditions.
While facing legal challenges and NDA submission delays, Corcept has opportunities to leverage its pipeline and market strategies for future success.

Corcept Therapeutics reports strong Q3 earnings and advances pipeline

Corcept Therapeutics delivered robust financial results, showing substantial revenue growth and profitability in Q3 2024. The company's pipeline progress and expanded revenue guidance underscore its strong market position and growth potential.
While facing legal challenges and complexities in clinical development, Corcept's strategic initiatives in multiple therapeutic areas and combination therapies position it well to capitalize on market opportunities and drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. It engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Corcept (CORT) Down 24.9% Since Last Earnings Report: Can It Rebound?

MENLO PARK, Calif., March  12, 2020  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that former Gilead Sciences executive Gregg Alton has joined Corcept’s Board of Directors. Mr. Alton has also been appointed as Chair of the Corporate Governance and Nominating Committee of the Board of Directors.

Corcept Therapeutics Appoints Gregg Alton to Board of Directors

Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.

Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y

Corcept Therapeutics, Inc. (CORT) CEO Joseph Belanoff on Q4 2019 Results - Earnings Call Transcript

Corcept (CORT) delivered earnings and revenue surprises of 0.00% and -0.01%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Meets Q4 Earnings Estimates

Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Corcept (CORT) Could Beat Earnings Estimates Again

During Corcept's (CORT) Q4 earnings call, investor focus will be on the sales uptake of its Cushing's syndrome drug Korlym and other pipeline updates.

What's in Store for Corcept (CORT) This Earnings Season?

Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Corcept Therapeutics (CORT) to Report Q4 Results: What Awaits?

MENLO PARK, Calif., Jan.  30, 2020  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the stress hormone cortisol, today reported preliminary fourth quarter revenue of $87.9 million, compared to $66.8 million in the fourth quarter of 2018.  Preliminary 2019 revenue was $306.5 million, an increase of 22 percent from 2018. 

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2019 Preliminary Selected Financial Results; Provides 2020 Revenue Guidance

Despite The Clouds Hanging Over Korlym Sales, Corcept Therapeutics Still Looks An Attractive Investment

Why Is Corcept (CORT) Down 8.9% Since Last Earnings Report?

The company's fight to keep generic competition at bay took a turn for the worse.

Here's Why Corcept Therapeutics Stock Hit the Bricks Today

As of late, it has definitely been a great time to be an investor Corcept Therapeutics.

Can The Uptrend Continue for Corcept Therapeutics?

Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Corcept (CORT) Stock

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2019 Results - Earnings Call Transcript

Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.

Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales

Corcept (CORT) delivered earnings and revenue surprises of 15.79% and 5.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Surpasses Q3 Earnings and Revenue Estimates

Why Corcept (CORT) is Poised to Beat Earnings Estimates Again

MENLO PARK, Calif., Sept.  18, 2019  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Kimberly Park has joined the company’s Board of Directors.

Corcept Therapeutics Appoints Kimberly Park to Board of Directors

Atrion

Merit Medical Systems

National Research Corp

Supernus Pharmaceuticals

According to the GuruFocus All-In-One Screener as of Friday, the following health care stocks are popular among gurus.

5 Health Care Stocks - Gurus Are Buying

Corcept (CORT) Up 15.1% Since Last Earnings Report: Can It Continue?

MENLO PARK, Calif., Aug.  28, 2019  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the administration of Korlym® with food.  The patent will expire in November 2032.

Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome

Liver Therapy Forum weekly digest provides an overview of what’s happening in therapeutics for endocrine disease in 2019. This week’s focus is Corcept Therapeutics.

Corcept Therapeutics And Relacorilant In Cushing's Syndrome

Corcept (CORT) misses earnings and revenue estimates in the second quarter of 2019.

Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2

Corcept Therapeutics Inc. (CORT) CEO Joseph Belanoff on Q2 2019 Results - Earnings Call Transcript

News for Corcept Therapeutics Stock (CORT)